[
  {
    "ts": null,
    "headline": "Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly decreased disease activity and severity in patients with moderate-to-severe disease.1",
    "url": "https://finnhub.io/api/news?id=c86fb7f8ae95bffdf41e3b7ce4ab943935b5e44e9634f5d5c1ad3fc94d254ae4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761345120,
      "headline": "Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies",
      "id": 137216028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly decreased disease activity and severity in patients with moderate-to-severe disease.1",
      "url": "https://finnhub.io/api/news?id=c86fb7f8ae95bffdf41e3b7ce4ab943935b5e44e9634f5d5c1ad3fc94d254ae4"
    }
  },
  {
    "ts": null,
    "headline": "GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short",
    "summary": "GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.",
    "url": "https://finnhub.io/api/news?id=81411fc6099e1c4fca23e207cfc1979aa83ee43b1525337576aa3dcd1571558f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761336770,
      "headline": "GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short",
      "id": 137216029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.",
      "url": "https://finnhub.io/api/news?id=81411fc6099e1c4fca23e207cfc1979aa83ee43b1525337576aa3dcd1571558f"
    }
  },
  {
    "ts": null,
    "headline": "Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs",
    "summary": "Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.",
    "url": "https://finnhub.io/api/news?id=fef1e73965e5b9794217b3c7ef7483d653b03c44ce7e464915489e38b2911be2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761319860,
      "headline": "Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs",
      "id": 137214515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.",
      "url": "https://finnhub.io/api/news?id=fef1e73965e5b9794217b3c7ef7483d653b03c44ce7e464915489e38b2911be2"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Non-Oncology Drugs Q3 Performance: What to Expect",
    "summary": "MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.",
    "url": "https://finnhub.io/api/news?id=a495ba94edf3b314d66e89597bef0a858857553e06dd26275f1c5513e830a084",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761314700,
      "headline": "Merck's Non-Oncology Drugs Q3 Performance: What to Expect",
      "id": 137216031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.",
      "url": "https://finnhub.io/api/news?id=a495ba94edf3b314d66e89597bef0a858857553e06dd26275f1c5513e830a084"
    }
  },
  {
    "ts": null,
    "headline": "Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescents) with plaque psoriasis (PsO) affecting high-impact sites.",
    "url": "https://finnhub.io/api/news?id=2a650b12f5fbf8d4873f4b4c06d2a880d87e2cbe068ff9c6311bc998f19e2283",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761307200,
      "headline": "Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis",
      "id": 137216032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescents) with plaque psoriasis (PsO) affecting high-impact sites.",
      "url": "https://finnhub.io/api/news?id=2a650b12f5fbf8d4873f4b4c06d2a880d87e2cbe068ff9c6311bc998f19e2283"
    }
  },
  {
    "ts": null,
    "headline": "What To Expect From Gilead In Q3 2025",
    "summary": "Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting. Check out why GILD stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=b5f5ee55f87366db308381563df757bde2335123cbe5c6ab532f82054c10ff85",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761303403,
      "headline": "What To Expect From Gilead In Q3 2025",
      "id": 137202475,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/728909377/image_728909377.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting. Check out why GILD stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=b5f5ee55f87366db308381563df757bde2335123cbe5c6ab532f82054c10ff85"
    }
  },
  {
    "ts": null,
    "headline": "NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control",
    "summary": "PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along with the tr",
    "url": "https://finnhub.io/api/news?id=2f378fec38bf547b9c88bbe5265d9287e6ce2312f33712211fa04f2f824a1827",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761285600,
      "headline": "NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control",
      "id": 137216033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along with the tr",
      "url": "https://finnhub.io/api/news?id=2f378fec38bf547b9c88bbe5265d9287e6ce2312f33712211fa04f2f824a1827"
    }
  },
  {
    "ts": null,
    "headline": "Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning",
    "summary": "Invesco highlights strategic fund shifts and key contributors driving Q3 growth. Explore how smart repositioning supports long-term potentialâread the full update.",
    "url": "https://finnhub.io/api/news?id=1ce4d328f1a2874bd45e9b25f925cf2c759f7c0ee73e7aa7f6f6038fe80df53a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761280200,
      "headline": "Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning",
      "id": 137201175,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192908520/image_2192908520.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Invesco highlights strategic fund shifts and key contributors driving Q3 growth. Explore how smart repositioning supports long-term potentialâread the full update.",
      "url": "https://finnhub.io/api/news?id=1ce4d328f1a2874bd45e9b25f925cf2c759f7c0ee73e7aa7f6f6038fe80df53a"
    }
  }
]